SCHEMBL929385

SCHEMBL929385

CC1c2nc(-c3ccc(F)nc3)cn2CCN1C(=O)c1cc2ncc(Br)cn2n1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 4/20 0.47
ALDH1A1 P00352 3/20 0.47
ESR1 P03372 3/20 0.47
POLB P06746 2/20 0.47
TDP1 Q9NUW8 2/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
GRM5 P41594 13/20 0.42
KDM4E B2RXH2 1/20 0.41
HSD17B10 Q99714 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL929503 0.90 GRM5 (0.42) ESR2ALDH1A1ESR1POLBTDP1
SCHEMBL3821209 0.88 TACR3 (0.38) ESR2ALDH1A1ESR1POLBTDP1
SCHEMBL929437 0.85 TACR3 (0.51) ESR2ALDH1A1ESR1POLBTDP1
SCHEMBL930864 0.85 ESR2 (0.47) ESR2ALDH1A1ESR1POLBTDP1
SCHEMBL929465 0.84 GRM5 (0.47) ESR2ALDH1A1ESR1POLBTDP1
SCHEMBL931325 0.83 ALDH1A1 (0.53) ESR2ALDH1A1ESR1POLBTDP1
SCHEMBL3814901 0.81 TACR3 (0.38) ALDH1A1HPGDGRM5HSD17B10
SCHEMBL1010651 0.81 ESR2 (0.51) ESR2ALDH1A1ESR1POLBTDP1
SCHEMBL1009526 0.80 ESR2 (0.50) ESR2ALDH1A1ESR1POLBTDP1
SCHEMBL930056 0.80 ALDH1A1 (0.56) ESR2ALDH1A1ESR1POLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2085398-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine Merz Pharma GmbH & Co. KGaA (DE) 2009-08-05 EP claimed
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2011-01-06 US disclosed
EP-2247590-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE Merz Pharma GmbH & Co. KGaA (DE) 2010-11-10 EP disclosed
WO-2009095254-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2009-08-06 WO disclosed
EP-2085398-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine Merz Pharma GmbH & Co. KGaA (DE) 2009-08-05 EP disclosed
EP-2085398-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine Merz Pharma GmbH & Co. KGaA (DE) 2009-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE GRM5, GRIK5, GRK5 ESR2 3474/4885ALDH1A1 2888/4885ESR1 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.